Q3 EPS Forecast for Niagen Bioscience Decreased by Analyst

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimate for Niagen Bioscience down from $0.05 to $0.02, while maintaining a "Buy" rating and a $12.00 price target.
• Niagen's recent earnings report exceeded expectations with an EPS of $0.04 and revenue of $31.12 million, surpassing analyst estimates.
• Several analysts have differing outlooks on the stock, with Roth Capital increasing its price target to $23.00 and Wall Street Zen downgrading from "strong-buy" to "buy."

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - HC Wainwright dropped their Q3 2025 EPS estimates for Niagen Bioscience in a report released on Monday, August 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.02 per share for the quarter, down from their prior forecast of $0.05. HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. HC Wainwright also issued estimates for Niagen Bioscience's Q4 2025 earnings at $0.02 EPS, FY2025 earnings at $0.15 EPS, Q1 2026 earnings at $0.07 EPS and Q4 2026 earnings at $0.13 EPS.

Several other equities analysts have also recently weighed in on NAGE. Canaccord Genuity Group raised their target price on shares of Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Roth Capital reaffirmed a "buy" rating and set a $23.00 target price (up from $10.00) on shares of Niagen Bioscience in a research note on Friday, June 6th. Finally, Wall Street Zen raised shares of Niagen Bioscience from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $13.42.

Niagen Bioscience Stock Performance

Shares of NASDAQ NAGE traded down $0.57 during midday trading on Thursday, reaching $9.55. The stock had a trading volume of 348,330 shares, compared to its average volume of 947,347. The stock has a 50-day moving average of $11.50 and a 200-day moving average of $8.46. The company has a market capitalization of $761.64 million, a price-to-earnings ratio of 45.48 and a beta of 2.12. Niagen Bioscience has a 12-month low of $3.10 and a 12-month high of $14.69.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The firm had revenue of $31.12 million during the quarter, compared to analysts' expectations of $28.55 million. Niagen Bioscience had a net margin of 15.24% and a return on equity of 23.12%.

Hedge Funds Weigh In On Niagen Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming purchased a new position in shares of Niagen Bioscience in the 4th quarter worth $39,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Niagen Bioscience in the 4th quarter worth $53,000. Schonfeld Strategic Advisors LLC purchased a new position in shares of Niagen Bioscience in the 4th quarter worth $67,000. ProShare Advisors LLC purchased a new position in shares of Niagen Bioscience in the 4th quarter worth $74,000. Finally, Sherbrooke Park Advisers LLC purchased a new position in shares of Niagen Bioscience in the 4th quarter worth $94,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.